IMI
The European Commission Perspective

Ruxandra Draghia-Akli MD PhD
Director Health, Research and Innovation DG
European Commission

24th Annual EuroMeeting
26-28 March 2012
Copenhagen, Denmark
Objectives of IMI

- Better and faster medicines for patients
- New pre-competitive research tools
- The IMI JU is a Public-Private Partnership
  New approach to support research in FP7 Health Theme
- Re-invigorate the drug development process
- Increase competitiveness EU pharma sector
IMI Current Status

- 30 ongoing projects from 3 calls with ~300M € from IMI JU and ~270 M € from EFPIA companies
- 4th call: full project proposals being prepared
- 5th call launched on 6 March: European Lead Factory
- Solid reflection on remaining calls engaged: next call on antimicrobial resistance to be launched soon
Participation of EFPIA Companies in IMI and FP7 Health Projects

- EFPIA companies are involved in only few FP7 Health Projects (out of a total of about 700 projects)
- Strong involvement in IMI projects
- Based on share of projects, individual EFPIA companies are 25 to several hundred fold more involved in IMI projects
Experience with the Joint Technology Initiative Initiative IMI

• IMI projects perform excellent research
• Very good example of bringing research and innovation: IMIDIA project
• Leads to new forms of collaboration amongst stakeholders, built on trust: between academia and industry; also implicating regulators and patient organisations
• New business models for now and the future
• Rules and procedures need to be fit-for-purpose
First Human Pancreatic β Cell Line Developed by IMIDIA Project


IMI Education & Training Projects

- First course in Nov 2010 on drug discovery development
- Certificate and Master courses in pharmacovigilance and pharmaco-epidemiology in Sept 2011
- EU syllabus on pharmaceutical medicine
- Database on over 700 master courses, 110 professional development courses, 380 learning tools
Support for Clinical Trials in Partnership with Industry

• Upcoming IMI calls on antimicrobial resistance
• Development of markers and proof of principle clinical trials for such markers
• Prospectively following cohorts over longer duration
• Prevention clinical trials
Working Together in IMI and Beyond

- Ensuring more efficient and quicker decision on valid targets
- Thereby reducing risk of ‘omics’ targets
- To lay the basis for stratified therapies and personalised medicine
Horizon 2020: The next Framework Programme for Research and Innovation
Political Context for Horizon 2020

• Europe needs cutting edge research and innovation
• Essential to ensure competitiveness, growth and jobs
• Vital to tackle pressing societal challenges
• 3% of GDP invested in R&D: headline target of Europe 2020
Three Priorities

What’s New?

- Single programme
- More innovation – “from research to retail”
- Focus on societal challenges
- Simplified and broader access

Total budget € ~90 billion
Horizon 2020 and Partnering

Public-private partnerships:
• Through Joint Technology Initiatives or other formal structures (Art. 187)
• Through contractual agreements, which provide inputs for work programmes
• Only when criteria met, e.g. clear commitments from private partners

Also: public-public partnerships (e.g. ERA-Nets, Joint Programming Initiatives)
Thank you for your attention!

Find out more on Horizon 2020:

http://www.ec.europa.eu/research/horizon2020

ruxandra.draghia-akli@ec.europa.eu

http://ec.europa.eu/research/health

IMI Website

http://www.imi.europa.eu
Disclaimer

The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated.

These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.